Citation

BibTex format

@article{Szigeti:2024:10.1017/S0033291723003653,
author = {Szigeti, B and Weiss, B and Rosas, FE and Erritzoe, D and Nutt, D and Carhart-Harris, R},
doi = {10.1017/S0033291723003653},
journal = {Psychol Med},
pages = {1--8},
title = {Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression.},
url = {http://dx.doi.org/10.1017/S0033291723003653},
year = {2024}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - BACKGROUND: To investigate the association between pre-trial expectancy, suggestibility, and response to treatment in a trial of escitalopram and investigational drug, COMP360, psilocybin, in the treatment of major depressive disorder (ClinicalTrials.gov registration: NCT03429075). METHODS: We used data (n = 55) from our recent double-blind, parallel-group, randomized head-to-head comparison trial of escitalopram and investigational drug, COMP360, psilocybin. Mixed linear models were used to investigate the association between pre-treatment efficacy-related expectations, as well as baseline trait suggestibility and absorption, and therapeutic response to both escitalopram and COMP360 psilocybin. RESULTS: Patients had significantly higher expectancy for psilocybin relative to escitalopram; however, expectancy for escitalopram was associated with improved therapeutic outcomes to escitalopram, expectancy for psilocybin was not predictive of response to psilocybin. Separately, we found that pre-treatment trait suggestibility was associated with therapeutic response in the psilocybin arm, but not in the escitalopram arm. CONCLUSIONS: Overall, our results suggest that psychedelic therapy may be less vulnerable to expectancy biases than previously suspected. The relationship between baseline trait suggestibility and response to psilocybin therapy implies that highly suggestible individuals may be primed for response to this treatment.
AU - Szigeti,B
AU - Weiss,B
AU - Rosas,FE
AU - Erritzoe,D
AU - Nutt,D
AU - Carhart-Harris,R
DO - 10.1017/S0033291723003653
EP - 8
PY - 2024///
SP - 1
TI - Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression.
T2 - Psychol Med
UR - http://dx.doi.org/10.1017/S0033291723003653
UR - https://www.ncbi.nlm.nih.gov/pubmed/38247730
ER -